The CEO of Ampersand Biomedicines is teaching drugs the one thing they were never good at: knowing where to stop.
Most medicines are a message shouted at the whole body in the hope that the right organ is listening. The drug floods everywhere, does its job in one place, and causes trouble in a dozen others. For most of the history of drug development, that trade-off was simply the cost of doing business. Jason Gardner spent two decades deciding it did not have to be.
He runs Ampersand Biomedicines, a company whose name is a symbol - the ampersand, the &. It is not decoration. The whole thesis lives in that single character: the right molecule and the right location, together, non-negotiable. Ampersand builds what it calls AND-Body Therapeutics, biologics designed to switch on only when they arrive at the diseased tissue and to stay quiet everywhere else.
The engine behind them is the AND Platform, and even its acronym is a to-do list: Address, Navigate, Design. First find the biological address of the disease. Then figure out how a drug can navigate there. Then design a molecule that reads the map. It is a computational, multi-omics approach to a problem that pharma has mostly tried to muscle through with higher doses and better luck.
Gardner joined as CEO in August 2023, brought in by Flagship Pioneering, the venture-creation firm that hatched Moderna and dozens of other bets. Flagship does not usually hand a company to an outsider. It handed this one to a proven operator with a scientist's instincts and a track record of turning platforms into products.
“Creating medicines that specifically and safely act on the diseased organ or tissue and nowhere else has long been one of the greatest challenges in drug development.”
// Jason Gardner, on the problem he is trying to solveIdentify the precise biological address of a disease - the localization targets that make one tissue different from all the rest.
Work out how a biologic can actually get to that address and be recognized there, and nowhere it shouldn't be.
Computationally design the AND-Body Therapeutic that reads the map, activates on arrival, and leaves healthy tissue untouched.
Gardner did not arrive at the corner office by way of a business school case study. He arrived by way of a laboratory bench. His training reads like a tour of the oldest names in science: a bachelor's and master's in Natural Sciences, specializing in biochemistry, at the University of Cambridge, then a D.Phil. in Molecular Medicine at the University of Oxford. He crossed the Atlantic for a postdoctoral fellowship at Harvard Medical School, where he studied hematopoietic stem cells - the cells that quietly rebuild your blood every single day.
That stem-cell work would echo through everything after. His early industry years were spent as a Principal Scientist at Chiron Corporation and an Associate Director at Progenics Pharmaceuticals, learning how discoveries survive contact with the real world of manufacturing, regulators, and patients.
Then came GSK, where he grew from scientist to strategist. He ran the Center of Excellence for External Drug Discovery, overseeing more than forty programs across five therapeutic areas - essentially a portfolio manager for the future of a pharma giant. He founded and led GSK's Regenerative Medicine Unit from nothing, and as head of R&D in Boston he did something Big Pharma rarely does gracefully: he made friends. He built partnerships with the Harvard Stem Cell Institute and Italy's Telethon Institute for Gene Therapy, wiring a corporate lab into the open world of academic science.
In the mid-2010s he took the leap every scientist-turned-manager eventually faces: he co-founded his own company. As President and CEO of Magenta Therapeutics, he pushed programs into the clinic, took the company public through an IPO, and scaled it past one hundred employees. When Flagship went looking for someone to lead Ampersand, they were not hiring a resume. They were hiring a person who had already done the hard middle part - the part where a beautiful platform has to become an actual medicine.
Cambridge (biochemistry) → Oxford D.Phil. in molecular medicine → Harvard Medical School postdoc on hematopoietic stem cells.
Principal Scientist at Chiron Corporation; Associate Director at Progenics Pharmaceuticals.
Led the Center of Excellence for External Drug Discovery (40+ programs, five therapeutic areas); founded the Regenerative Medicine Unit; head of R&D in Boston.
Co-Founder, President & CEO of Magenta Therapeutics. Programs into the clinic, a successful IPO, and a team scaled past 100.
Named CEO of Ampersand Biomedicines and CEO-Partner at Flagship Pioneering.
Ampersand closes a $65M Series B, bringing total funding to roughly $115M.
AMP-220, a gut-targeted IL-22 AND-Body therapeutic, advances; a Genethon deal targets tissue-specific AAV vectors for gene therapy.
“I look forward to leading Ampersand on its mission to program smarter medicines and create a new paradigm in biologics discovery and development.”
// Jason Gardner, on taking the job“Jason brings extensive experience that spans the breadth of the biopharma industry, and his presence and leadership will greatly benefit Ampersand and Flagship's ecosystem.”
“Ampersand will benefit immensely from Jason's leadership, including his successful track record of scaling, partnering, and advancing novel therapeutics and bioplatforms across therapeutic areas.”
If you want to understand what Gardner actually does all day, look at the verbs that follow him around: scaling, partnering, advancing. Those are not the words of a lone genius hunched over a microscope. They are the words of someone who knows that modern medicine is a team sport played across universities, regulators, investors, and dozens of specialists who have to be pointed in the same direction.
At GSK he was the rare corporate scientist who opened doors rather than closing them. Building partnerships with the Harvard Stem Cell Institute and the Telethon Institute for Gene Therapy meant getting a slow-moving pharmaceutical giant to trust the messy, fast, unpredictable world of academic labs. That instinct - to connect rather than to hoard - is the same one that later let him raise money, recruit scientists, and stitch together the collaborations a young biotech lives or dies by.
It is also why his two quoted sentences about Ampersand are worth reading twice. He does not describe a product. He describes a mission and a paradigm. For a man trained to measure everything, the language is deliberately large - because the thing he is trying to build is not a single drug but a new way of thinking about where drugs belong.
A gut-targeted IL-22 AND-Body therapeutic - a biologic engineered to act in the gut and stay there. Preclinical data shared in 2026.
Computationally powered Address, Navigate, Design - multi-omics analysis feeding the design of site-specific biologics.
A 2026 collaboration to develop AAV vectors with enhanced tissue specificity - bringing the localization thesis to gene therapy.
The company is named after a punctuation mark. The platform is AND, the drugs are AND-Bodies. Rarely has a logo done this much scientific work.
He has now built a company off a Flagship-style platform twice - first Magenta, now Ampersand - after a long run inside Big Pharma at GSK.
British-trained at Cambridge and Oxford, he built his entire operating career in Boston, one of the densest biotech clusters on earth.
There is a pattern to how Jason Gardner works, and you can see it in both his molecules and his companies: he builds with a destination in mind. A drug is not just a payload; it is a payload plus an address. A company is not just a platform; it is a platform plus the discipline to turn it into something a patient can actually receive.
Ampersand is still early. AMP-220 is preclinical. The AND Platform has to prove, in human bodies and not just in silico, that a biologic can be told where to work and will obey. Biotech is littered with elegant ideas that never survived the clinic, and Gardner - who took Magenta public and watched programs meet the hard verdict of trials - knows this better than most.
But the ambition is unusually clean. Not a better version of an old drug. Not a marginal improvement in dosing. A different premise entirely: that the location of a drug's action can be programmed as deliberately as its chemistry. If it works, the phrase “side effect” starts to sound less like a law of nature and more like a design flaw someone finally fixed.
It helps that Gardner has been early before. Magenta was a platform bet too, and he carried it far enough to ring the opening bell. He knows exactly how many things have to go right between a clever idea and a treatment a doctor can prescribe, and he seems to have decided that knowing the odds is not a reason to stop - it is a reason to build carefully.
That is the wager written into a single character. The right medicine, and the right place. And.